Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. In this presentation, prof. Hobbs discusses the classic CV risk factors one by one.
Learn how bempedoic acid an ACL inhibtor works in reducing LDL-c
Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.
The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?
EAS 2019 Prof. Chris Packard distinguishes various types of biomarkers. Thinking about them in this way can provide a framework for more intelligent use of biomarkers.
Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.
Prof. Deanfield sheds light on the relation between T2DM and CVD, and how studies evaluating novel classes of antidiabetic drugs have evolved over time, from revealing safety signals to demonstrating CV benefit.
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.
PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.
Current CV risk scores overestimate risk in elderly and underestimate risk in young subjects. Prof. Frank Visseren emphasizes the need of CV lifetime risk prediction and presents the U-prevent calculator that estimates gain in CVD-free life based on lifetime CV risk and treatment effects in individuals.
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
Prof. John Deanfield introduces a new way of thinking about CV risk management in patients and population, to reduce the burden of CVD in society.
ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.
Clinical updates in management of cardiovascular risk Using data from large randomized clinical trials and from various cohorts, risk and treatment effects in individual patients can be predicted. Now even lifetime risk and lifetime treatment benefit can be predicted in terms of vascular disease-free life years gained.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Clinical updates in management of cardiovascular risk For lowering LDL-c, statins play a major role in both primary and secondary CV prevention in all patients. There is room for improvement with respect to choosing the right dosing regimen.
Clinical updates in management of cardiovascular risk CV risk factors that drive arterial disease in early life have a major impact on future CV risk. Communication about early lifestyle intervention to the public should be a major focus to reduce CV risk in later years.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
AHA 2017 Laura Stevens presented her poster on using artificial intelligence to identify risk factors for CVD and stroke. The found association with coffee was validated with traditional analyses.
CSI Rome Nicole Jaspers en Gijs Berkelmans discuss the role of precision medicine in secondary prevention with Dr. Noel Bairey Merz, as well as which approaches and types of data can be considered to assess risk.
CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.
The SAVE trial evaluated treatment of obstructive sleep apnea with continuous positive airway pressure in patients with CVD. McEvoy concludes there was no benefit for the composite CV endpoint, but a trend for stroke prevention in compliant patients, and QoL measures were improved.
Sandra Revill Tremulis, founder of the Lipoprotein(a) Foundation, shares her experiences as a patient with elevated Lp(a), and consequently a high CV risk, despite a healthy lifestyle.
In patients with elevated LDL-c and CRP, adding another lipid-lowering therapy may not adequately lower CV risk. Targeting residual inflammatory risk may be an effective strategy for secondary prevention.
Stanley Hazen discusses the connection between our gut microbiome and physiologic processes relevant to heart disease, via a pathway involving the metabolite TMAO.
Professor Ray discusses the HOPE-3 trial, in which CV risk was assessed without use of a comprehensive risk calculator. Statin therapy yielded a clear CV event reduction, while BP-lowering therapy did not. Combination therapy was only beneficial when baseline BP was >140 mmHg.
BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk
Dr Fitchett provides his perspective on the potential impact of the EMPA REG outcomes trial on the management of T2DM by cardiologists.
Dr. Robert Chilton, (Texas) discusses the results of the IRIS trial where treatment with PPAR-γ agonist pioglitazone
ACC 2016 Prof. Salim Yusuf discusses the results of the HOPE-3 study, which indicates that statins are effective in all patients with intermediate CVD risk, whereas blood pressure lowering is only effective in hypertensive patients.
The REACH registry demonstrated that CV risk factors are not adequately controlled worldwide. Prof. Deepak Bhatt (Boston, MA, USA) shares the evidence for preventive strategies and considers how the new PCSK9 inhibitors fit into CV risk management.
Prof Deanfield discusses the rationale for glucose control and CV risk reduction
Prof. Ray defends the proposition 'Statins are enough for the prevention of CVD' and considers the opposing standpoint in the plenary 'Controversy session' entitled 'Statin therapy vs. novel interventions'. Ray thinks more CVD could be prevented if more people globally would have access to statins. Is it time to add statins to drinking water, then?
Lipid MC 2015 Prof. Kausik Ray highlights differences in recommendations between international lipid guidelines, which originate in differences between the scopes of the documents. These differences have consequences for the recommended approach to reduce CV risk in patients.
Lipid MC 2015 Prof. Erik Stroes emphasises the care and attention needed when managing patients with statin-attributed muscle symptoms. Patients should be counselled on the benefit of statins to reduce CV risk and statin rechallenges may be effective.
Lipid MC 2015 Prof. Kausik Ray provides several reasons why non-HDL-c may be a better lipid parameter than LDL-c to assess risk, to identify high-risk patients and guide treatment.
Prof. Susekov, Moscow, with a brief update on current challenges to manage CVD in Russia, including some take home messages for Russian physicians
Prof. John E Deanfield highlights the key messages of JBS3: a new approach to CVD prevention, considering 'lifetime CV risk' and 'heart age'.